0001140361-17-037024.txt : 20170929 0001140361-17-037024.hdr.sgml : 20170929 20170929201742 ACCESSION NUMBER: 0001140361-17-037024 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170927 FILED AS OF DATE: 20170929 DATE AS OF CHANGE: 20170929 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Resnick Joshua CENTRAL INDEX KEY: 0001690959 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36830 FILM NUMBER: 171112898 MAIL ADDRESS: STREET 1: ONE BOSTON PLACE STREET 2: 201 WASHINGTON STREET, SUITE 3900 CITY: BOSTON STATE: MA ZIP: 02108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200915291 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 200, STE. 2203 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: (857) 999-0075 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 200, STE. 2203 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Therapeutics, Inc. DATE OF NAME CHANGE: 20140916 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery, Inc DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery Inc DATE OF NAME CHANGE: 20060105 4 1 doc1.xml FORM 4 X0306 4 2017-09-27 0 0001348911 KalVista Pharmaceuticals, Inc. KALV 0001690959 Resnick Joshua ONE BOSTON PLACE, SUITE 3900 201 WASHINGTON STREET, SUITE 3900 BOSTON MA 02108 1 0 0 0 Director Stock Option (Right to Buy) 6.71 2017-09-27 4 A 0 6000 0 A 2027-09-26 Common Stock 6000 6000 D The option vests over a 12 month period: 1/12th on October 27, 2017, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. The option is held by the reporting person for the benefit of SV Health Investors, LLC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. /s/Benjamin Palleiko, Attorney-in-Fact 2017-09-29